Directly Contact Organization
Save Project as XML
Details |
| Project Title | Yeast-Based Intein Platform for Drug Production | |
|---|---|---|
| Track Code | P150056US02 | |
| Website | http://www.warf.org/technologies/summary/P150056US02.cmsx | |
| Short Description | The therapeutic and biochemical properties of proteins including antibodies can be enhanced by custom chemical functionalization that enables modifications, such as small molecule drug conjugation, PEGylation and conjugation to nanoparticles. Expressed protein ligation (EPL) is one common approach to chemically modify proteins in a site-specific manner. In EPL, the target protein is expressed as a fusion partner to a non-self-cleaving intein such as Mxe GyrA, which is able to excise itself and join the remaining portions. These fusion proteins are most often expressed in E. coli bacteria. However, there are many disadvantages to using bacteria for fusion protein production. Drawbacks include protein refolding, instability and high loss (up to 90 percent) of the intein during expression. Yeast provide a promising alternative to bacterial expression systems, given their eukaryotic nature and quality control mechanisms. To fully realize the advantages of a yeast-based platform, novel inteins must be developed to increase production.\r\n\r\nUW–Madison researchers have engineered non-self-cleaving Mxe GyrA inteins shown to significantly improve the production of fusion proteins from Saccharomyces cerevisiae. The novel inteins were developed through directed evolution, and they enhance fusion protein display (up to 3x) and secretion levels (up to 30x) compared to the wild type intein. The new yeast-based platform provides a robust alternative to bacterial intein expression systems. | |
| Abstract | The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing engineered inteins for improved production of fusion proteins in yeast. | |
| Tags | biotechnology, drug production, intein | |
| Posted Date | Jul 19, 2017 9:22 PM | |
Advantages |
- Significantly improves fusion protein display and secretion levels
- Competitive alternative to bacteria-based systems
Potential Applications |
- Target end users include pharmaceutical or biotech partners interested in developing protein biologic drug conjugates
- Kit for enhancing production of fusion proteins in yeast Research tools
Additional Information |
Contact Information |
TTO Home Page: http://www.warf.org
Name : Jennifer Gottwald
Title : Director of Licensing
Department : Licensing
Email : jennifer@warf.org
Phone : 608-960-9854
Address : 614 Walnut Street, 13th floor, Madison, WI 53726
Principal Investigator |
Name : Cathryn Marshall
Department : Chemical Engineering
Name : Eric Shusta
Department : Chemical Engineering
Intellectual Property |
Patent Number : 9,771,412
Patent Title : ENGINEERED INTEIN FOR IMPROVED PRODUCTION OF PROTIEN-INTEIN FUSIONS
Patent Application Date : Oct 29, 2015
Patent Publication Date : May 5, 2016
Patent Issue Date : Sep 26, 2017
Patent Link : http://www.warf.org/documents/ipstatus/P150056US02.PDF